Literature DB >> 21683076

Mycobacterium bovis Bacillus Calmette-Guérin killed by extended freeze-drying reduces colitis in mice.

Micheline Lagranderie1, Christoph Kluge, Helene Kiefer-Biasizzo, Mohammad Abolhassani, Marie-Anne Nahori, Catherine Fitting, Michel Huerre, Antonio Bandeira, Herve Bercovier, Gilles Marchal.   

Abstract

BACKGROUND & AIMS: Mycobacterium bovis Bacillus Calmette-Guérin (BCG), killed by extended freeze-drying (EFD), induces secretion of interleukin-10 and reduces lung inflammation in a mouse model of asthma. We investigated the effects of EFD BCG in mouse models of inflammatory bowel disease.
METHODS: EFD BCG was administered subcutaneously to mice with colitis induced by dextran sodium sulfate (DSS), oxazolone, or adoptive transfer of CD4(+)CD45RB(high)Foxp3(-) T cells from C57Bl/6 Foxp3GFP mice to RAG2(-/-) mice.
RESULTS: EFD BCG, administered either before induction of DSS and oxazolone colitis or after development of acute or chronic DSS-induced colitis, reduced symptom scores, loss of body weight, and inflammation. Although transfer of CD4(+)CD45RB(high)Foxp3(-) cells induced colitis in RAG2(-/-) mice, administration of EFD BCG at the time of the transfer converted Foxp3(-) T cells to Foxp3(+) T cells and the mice did not develop colitis. EFD BCG protected mice from colitis via a mechanism that required expansion of T regulatory cells and production of interleukin-10 and transforming growth factor β. EFD BCG activated the retinoid X receptor (RXR)-α-peroxisome proliferator-activated receptor (PPAR)-γ heterodimer, blocked translocation of nuclear factor κB to the nucleus, and reduced colonic inflammation; it did not increase the number of colon tumors that formed in mice with chronic DSS-induced colitis.
CONCLUSIONS: EFD BCG controls severe colitis in mice by expanding T regulatory cell populations and PPAR-γ and might be developed to treat patients with inflammatory bowel disease.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683076     DOI: 10.1053/j.gastro.2011.05.002

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice.

Authors:  Hai-Mei Zhao; Xiao-Ying Huang; Zhi-Qin Zuo; Qi-Hong Pan; Mei-Ying Ao; Feng Zhou; Hong-Ning Liu; Zhi-Yong Liu; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 2.  Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination.

Authors:  Mardi C Boer; Simone A Joosten; Tom H M Ottenhoff
Journal:  Front Immunol       Date:  2015-05-11       Impact factor: 7.561

3.  Enlarged colitogenic T cell population paradoxically supports colitis prevention through the B-lymphocyte-dependent peripheral generation of CD4(+)Foxp3(+) Treg cells.

Authors:  Fábio Barrozo do Canto; Sylvia Maria Nicolau Campos; Alessandra Granato; Rafael F da Silva; Luciana Souza de Paiva; Alberto Nóbrega; Maria Bellio; Rita Fucs
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

4.  Extended Freeze-Dried BCG Instructed pDCs Induce Suppressive Tregs and Dampen EAE.

Authors:  Carla Lippens; Laure Garnier; Pierre-Marie Guyonvarc'h; Marie-Laure Santiago-Raber; Stéphanie Hugues
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

Review 5.  Trained Immunity Contribution to Autoimmune and Inflammatory Disorders.

Authors:  Samanta C Funes; Mariana Rios; Ayleen Fernández-Fierro; María S Di Genaro; Alexis M Kalergis
Journal:  Front Immunol       Date:  2022-04-08       Impact factor: 8.786

6.  Mannose-capped lipoarabinomannan-induced B10 cells decrease severity of dextran sodium sulphate-induced inflammatory bowel disease in mice.

Authors:  Chun-Hui Yuan; Xin Li; Liang Luo; Ya-Ping Wang; Dong-Li Zhang; Kai-Liang Zhou; Xiao-Lian Zhang; Qin Pan
Journal:  Scand J Immunol       Date:  2019-11-24       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.